NCT03468010 is a Phase 3 clinical trial of chemoradiation in Cervical Cancer, sponsored by Sun Yat-sen University.

Who is sponsoring NCT03468010?

NCT03468010 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT03468010?

Interventions in NCT03468010: chemoradiation, Paclitaxel, Cisplatin.

What condition does NCT03468010 study?

NCT03468010 studies Cervical Cancer, Adjuvant Chemotherapy, Radiation, Lymph Node Metastases.

Is NCT03468010 still recruiting?

NCT03468010 is currently status unknown. Last updated 26 March 2018.

Last reviewed 2018-03-26 · How we verify

NCT03468010

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial Comparing Adjuvant Chemotherapy With Observation After Concurrent Chemoradiotherapy of Cervical Cancer (With Pelvic or Para-aortic Node Involvement)

Status unknown Phase 3 Last updated 26 March 2018

What this trial tests

Phase 3 trial testing chemoradiation in Cervical Cancer in 432 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
1 March 2025

1 March 2025

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	432
Start date	1 March 2018
Primary completion	1 March 2025
Estimated completion	1 March 2025
Sites	8 locations across China

Drugs / interventions tested

chemoradiation — full drug profile →
Paclitaxel, Cisplatin

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →
Adjuvant Chemotherapy — all drugs for Adjuvant Chemotherapy →
Radiation — all drugs for Radiation →
Lymph Node Metastases — all drugs for Lymph Node Metastases →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 70, female only, with Cervical Cancer or Adjuvant Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cervical cancer with pelvic or para-aortic node involvement has a poor prognosis. Despite low-quality data, the routine practice to treat these patients is radiation with concurrent cisplatin. The aim of this study is to compare systemic chemotherapy with observation after radiation with concurrent cisplatin of cervical cancer ( with pelvic or para-aortic node involvement) for incidence of adverse events and local recurrence rate.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA.
Leung E, Han K, Zou J, Zhao Z, et al · · 2021 · cited 70× · PMID 34580115 · DOI 10.1158/1078-0432.ccr-19-2384
Cervical cancer heterogeneity: a constant battle against viruses and drugs.
Sun Q, Wang L, Zhang C, Hong Z, et al · · 2022 · cited 28× · PMID 36397138 · DOI 10.1186/s40364-022-00428-7
Should the Number of Metastatic Pelvic Lymph Nodes be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?
Pedone Anchora L, Carbone V, Gallotta V, Fanfani F, et al · · 2020 · cited 28× · PMID 32545508 · DOI 10.3390/cancers12061552

Verify or expand the search:

Other trials of chemoradiation

Trials testing the same drug.

NCT04135664 — Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma · Phase 3 · recruiting

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03468010 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 26 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03468010.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing